267 related articles for article (PubMed ID: 25355593)
1. An overview on the development of new potentially active camptothecin analogs against cancer.
Chazin Ede L; Reis Rda R; Junior WT; Moor LF; Vasconcelos TR
Mini Rev Med Chem; 2014; 14(12):953-62. PubMed ID: 25355593
[TBL] [Abstract][Full Text] [Related]
2. Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan.
Mathijssen RH; Loos WJ; Verweij J; Sparreboom A
Curr Cancer Drug Targets; 2002 Jun; 2(2):103-23. PubMed ID: 12188913
[TBL] [Abstract][Full Text] [Related]
3. An overview of topoisomerase I-targeting agents.
Arbuck SG; Takimoto CH
Semin Hematol; 1998 Jul; 35(3 Suppl 4):3-12. PubMed ID: 9779876
[TBL] [Abstract][Full Text] [Related]
4. The development of camptothecin analogs in childhood cancers.
Bomgaars L; Berg SL; Blaney SM
Oncologist; 2001; 6(6):506-16. PubMed ID: 11743213
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and antitumor activity of novel substituted uracil-1'(N)-acetic acid ester derivatives of 20(S)-camptothecins.
Li DZ; Zhang QZ; Wang CY; Zhang YL; Li XY; Huang JT; Liu HY; Fu ZD; Song HX; Lin JP; Ji TF; Pan XD
Eur J Med Chem; 2017 Jan; 125():1235-1246. PubMed ID: 27871039
[TBL] [Abstract][Full Text] [Related]
6. Topoisomerase I inhibitors. An overview of the camptothecin analogs.
Burris HA; Fields SM
Hematol Oncol Clin North Am; 1994 Apr; 8(2):333-55. PubMed ID: 8040144
[TBL] [Abstract][Full Text] [Related]
7. Camptothecin's journey from discovery to WHO Essential Medicine: Fifty years of promise.
Khaiwa N; Maarouf NR; Darwish MH; Alhamad DWM; Sebastian A; Hamad M; Omar HA; Orive G; Al-Tel TH
Eur J Med Chem; 2021 Nov; 223():113639. PubMed ID: 34175539
[TBL] [Abstract][Full Text] [Related]
8. Two novel camptothecin derivatives inhibit colorectal cancer proliferation via induction of cell cycle arrest and apoptosis in vitro and in vivo.
Du H; Huang Y; Hou X; Quan X; Jiang J; Wei X; Liu Y; Li H; Wang P; Zhan M; Ai X; Lu L; Yuan S; Sun L
Eur J Pharm Sci; 2018 Oct; 123():546-559. PubMed ID: 30118848
[TBL] [Abstract][Full Text] [Related]
9. Evolution in medicinal chemistry of E-ring-modified Camptothecin analogs as anticancer agents.
Huang Q; Wang L; Lu W
Eur J Med Chem; 2013 May; 63():746-57. PubMed ID: 23578545
[TBL] [Abstract][Full Text] [Related]
10. The current status of camptothecin analogues as antitumor agents.
Slichenmyer WJ; Rowinsky EK; Donehower RC; Kaufmann SH
J Natl Cancer Inst; 1993 Feb; 85(4):271-91. PubMed ID: 8381186
[TBL] [Abstract][Full Text] [Related]
11. Topoisomerase I inhibitors: topotecan and irenotecan.
Creemers GJ; Lund B; Verweij J
Cancer Treat Rev; 1994 Jan; 20(1):73-96. PubMed ID: 8293429
[No Abstract] [Full Text] [Related]
12. Synthesis of 9-(heteroarylmethylidene)amino derivatives of homocamptothecin with biological activities.
Guo W; Miao Z; Sheng C; Yao J; Liu W; Zhu L; Zhang Y; Cheng P; Dong G; Zhuang C; Zhang W
Chem Biodivers; 2011 Jul; 8(7):1266-73. PubMed ID: 21766447
[TBL] [Abstract][Full Text] [Related]
13. Topoisomerase I inhibitors in the treatment of colorectal cancer.
Rothenberg ML; Blanke CD
Semin Oncol; 1999 Dec; 26(6):632-9. PubMed ID: 10606256
[TBL] [Abstract][Full Text] [Related]
14. Improved anti-tumor activity of fluorinated camptothecin derivatives 9-fluorocamptothecin and 7-ethyl-9-fluorocamptothecin on hepatocellular carcinoma by targeting topoisomerase I.
Zhang M; Zhu LZ; Yang CJ; Yan JX; Wang ZP; Bai YP; Peng LZ; Luo HB; Zhang ZJ; Li L; Xu CR; Liu YQ
Bioorg Chem; 2023 Oct; 139():106652. PubMed ID: 37390632
[TBL] [Abstract][Full Text] [Related]
15. Clinical applications of the camptothecins.
Takimoto CH; Wright J; Arbuck SG
Biochim Biophys Acta; 1998 Oct; 1400(1-3):107-19. PubMed ID: 9748525
[TBL] [Abstract][Full Text] [Related]
16. Clinical trials with the topoisomerase I inhibitors.
Burris HA; Rothenberg ML; Kuhn JG; Von Hoff DD
Semin Oncol; 1992 Dec; 19(6):663-9. PubMed ID: 1334279
[TBL] [Abstract][Full Text] [Related]
17. [Topoisomerase I inhibitors. Review of phase II trials with irinotecan (CPT-11) and topotecan].
Bonneterre J
Bull Cancer; 1995 Aug; 82(8):623-8. PubMed ID: 7492818
[TBL] [Abstract][Full Text] [Related]
18. Camptothecin analogues in the treatment of non-small cell lung cancer.
Ardizzoni A
Lung Cancer; 1995 Apr; 12 Suppl 1():S177-85. PubMed ID: 7551927
[TBL] [Abstract][Full Text] [Related]
19. DX-8951f, a water-soluble camptothecin analog, exhibits potent antitumor activity against a human lung cancer cell line and its SN-38-resistant variant.
Joto N; Ishii M; Minami M; Kuga H; Mitsui I; Tohgo A
Int J Cancer; 1997 Aug; 72(4):680-6. PubMed ID: 9259410
[TBL] [Abstract][Full Text] [Related]
20. Homocamptothecins: potent topoisomerase I inhibitors and promising anticancer drugs.
Bailly C
Crit Rev Oncol Hematol; 2003 Jan; 45(1):91-108. PubMed ID: 12482574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]